Clinical Trial Update: High-dose Methylprednisolone and Rituximab in High Risk B-CLL [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating high-dose methylprednisolone with rituximab in high-risk chronic lymphocytic leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Rituxan (rituximab)
• SOLU-MEDROL (Methylprednisolone sodium succinate)

Snippet

Sponsor: Vilnius University | Conditions: Chronic B-Lymphocytic Leukemia | Phase 2 | Status: COMPLETED